12 research outputs found
Enrollment and patient disposition.
<p><sup>a</sup>Other reasons (more than one reason may apply to a given patient): no final confirmation from the investigator (n = 56); contraindications to therapy (n = 15); HCV RNA-negative at screening/baseline (n = 12); end-stage renal disease (n = 7); major organ transplantation (n = 2); not treated with peginterferon alfa (n = 1) or ribavirin (n = 2); acute hepatitis C (n = 1); co-infection with HIV (n = 115); co-infection with HBV (n = 74); treatment with regimen other than peginterferon alfa-2a/ribavirin or peginterferon alfa-2b/ribavirin (n = 14); treatment-naive and intended treatment duration of 72 weeks (n = 6).</p
SVR rates according to exposure and baseline prediction score in subgroup 2.
<p>SVR rates according to exposure and baseline prediction score in subgroup 2.</p
SVR24 rates by incidence of safety-related dose reductions or discontinuations by Week 4 and Week 12 of treatment in genotype 1 patients assigned to 48 weeks of treatment with peginterferon alfa-2a/ribavirin.
<p>Fisher’s exact test, two-sided P-value. (A) Subgroup 1: all treatment-naive genotype 1 patients (n = 1497); (B) Subgroup 2: treatment-naive, genotype 1, noncirrhotic Caucasian patients (n = 951).</p
SVR rates according to exposure and time of first sr-RD in the overall population.
<p>SVR rates according to exposure and time of first sr-RD in the overall population.</p
SVR24 rates by baseline predictive score and by incidence of safety-related dose reductions or discontinuations by Week 4 and Week 12 of treatment in subgroup 2 (Caucasian, treatment-naive, G1 noncirrhotic patients assigned to 48 weeks of treatment with peginterferon alfa-2a/ribavirin).
<p>Fisher’s exact test, two-sided P-value. Please note that 34 patients had unknown baseline score.</p
Multiple logistic regression analysis of baseline and on-treatment factors associated with SVR24 in Caucasian, treatment-naive, G1, noncirrhotic patients assigned to 48 weeks of treatment with PegIFN alfa-2a/RBV.
<p>Patients who discontinued therapy for efficacy or other non-safety reasons were excluded. <sup>a</sup>Effect P-value: P = 0.0316 for sr-RD and 0.0001 for missed ribavirin days in percentage of target.</p
Cox proportional hazards analysis for time to first safety-related dose reductions or discontinuations in patients treated for 24 or 48 weeks with peginterferon alfa-2a or alfa-2b and ribavirin.
<p>(A) All treatment-naive patients (G1–6) assigned to 24 or 48 weeks of treatment with peginterferon alfa-2a or alfa-2b/RBV (N = 3181); (B) Subgroup 2: treatment-naive Caucasian, G1 noncirrhotic patients assigned to 48 weeks of treatment with peginterferon alfa-2a/RBV (n = 951).</p
Scoring system used to identify patients in subgroup 2<sup>a</sup> with a high or low probability of achieving SVR24.
<p>Scoring system used to identify patients in subgroup 2<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0151703#t001fn001" target="_blank"><sup>a</sup></a> with a high or low probability of achieving SVR24.</p
Modifications of liver disease stage following DAA treatment in patients with cirrhosis.
<p>(A) Baseline, post-failure and post-retreatment SVR12 changes of Child Pugh Class; (B) baseline and post-failure changes of Child Pugh Class for patients who were not retreated yet; (C) baseline and post-SVR12 changes of Child Pugh Class for patients who achieved SVR12 following the first DAA treatment. Bold arrows indicate patients who did not change the Child Pugh Class. Dashed arrows indicate patients who worsened the Child Pugh Class, whereas the grey arrows indicate patients who improved the Child Pugh class. In the curly brackets are reported the number of patients for specific changes observed in the Child Pugh classes in the three points of evaluation. n = number of patients.</p
Univariate and logistic regression analysis linking failure with independent variables.
<p>Univariate and logistic regression analysis linking failure with independent variables.</p